ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VERV Verve Therapeutics Inc

13.55
0.36 (2.73%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 647,690
Bid Price 12.90
Ask Price 13.32
News (1)
Day High 13.63

Low
8.22

52 Week Range

High
21.4199

Day Low 12.94
Company Name Stock Ticker Symbol Market Type
Verve Therapeutics Inc VERV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.36 2.73% 13.55 20:00:00
Open Price Low Price High Price Close Price Prev Close
13.28 12.94 13.63 13.28 13.19
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,846 647,690 $ 13.35 $ 8,646,381 - 8.22 - 21.4199
Last Trade Time Type Quantity Stock Price Currency
19:23:21 75 $ 13.28 USD

Verve Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.11B 83.62M - 11.76M -200.07M -2.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Verve Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VERV Message Board. Create One! See More Posts on VERV Message Board See More Message Board Posts

Historical VERV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.6114.261412.6513.07659,142-0.06-0.44%
1 Month18.9619.3412.6514.461,164,277-5.41-28.53%
3 Months13.0519.3410.310313.581,085,3990.503.83%
6 Months12.5820.128.2212.681,390,7170.977.71%
1 Year14.5921.41998.2213.811,023,845-1.04-7.13%
3 Years30.0078.008.2222.69842,380-16.45-54.83%
5 Years30.0078.008.2222.69842,380-16.45-54.83%

Verve Therapeutics Description

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Your Recent History

Delayed Upgrade Clock